HUTCHMED
↗Hong Kong
HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Founded in 2000 with the MediPharma pivot in 2001, the company has evolved from consolidating the fragmented Traditional Chinese Medicine market to pursuing novel, small-molecule inhibitors and advanced modalities for cancer and immunology. HUTCHMED leverages its in-house novel drug discovery and development engine to create a broad pipeline of differentiated clinical and late pre-clinical stage drug candidates. The company operates as a truly global organization with approximately 900 scientists and staff distributed across Shanghai (R&D hub) and Florham Park, New Jersey (International headquarters and clinical operations), enabling rapid global development of its innovative pipeline.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology & Immunology Biotech
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$548.5M (2025 total consolidated revenue); Oncology/Immunology 2026 guidance: $330-450M
Founded:2000
Ownership:public
Status:operating
FUNDING
Stage:Public Company
Investors:CK Hutchison Holdings (majority shareholder)
STOCK
Exchange:NASDAQ/AIM/Hong Kong Exchange
Ticker:HCM (NASDAQ); HCM (AIM); 13 (HKEX)
Market Cap:$2.4-3.4B
PIPELINE
Stage:Discovery to Phase III
Lead Drug Stage:Phase III (multiple programs) / Commercial (China approvals)
Modalities:Small molecule inhibitors, Monoclonal antibodies, ATTC (Antibody-Targeted Therapy Conjugates), Targeted therapeutics, Immunotherapies
Active Trials:15
Trial Phases:Phase 1: 2 | Phase 2: 4 | Phase 3: 8 | Phase 4: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Takeda Pharmaceutical: Fruquintinib global development (up to $1.13B deal including $400M upfront, 2022), Eli Lilly: Fruquintinib co-development and commercialization in China (shared costs, milestone payments, royalties), AstraZeneca: Savolitinib joint development and commercialization globally under ORPATHYS® brand
COMPETITION
Position:Leader
Competitors:BeiGene (tislelizumab, zanubrutinib), CStone Pharmaceuticals (CS1001, immuno-oncology focus), Innovent Biologics (sintilimab), CARsgen Therapeutics (CAR-T cell therapy), JW Therapeutics (cell therapy), Junshi Biosciences (nasopharyngeal carcinoma focus), Bayer (Stivarga - competes in colorectal cancer), Taiho Pharmaceutical (Lonsurf - competes in colorectal cancer)
LEADERSHIP
Key Executives:
Dan Eldar - Chairman
Weiguo SU - Executive Director, CEO (on leave of absence)
Johnny CHENG - Executive Director, Acting CEO and CFO
George YUAN - Executive Vice President
Guangxiu DAI - Executive Vice President
Johnathan LEE - Executive Vice President
Steven HU - Executive Vice President
May WANG - Executive Vice President
Yiling CUI - Executive Vice President
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of HUTCHMED and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with HUTCHMED. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.